REFERENCES
1. Spencer MR, Miniño AM, Warner M. Drug Overdose Deaths in the United States, 2001-2021. NCHS Data Brief . Dec 2022;(457):1-8.
2. Ciccarone D. The triple wave epidemic: Supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy . Sep 2019;71:183-188. doi:10.1016/j.drugpo.2019.01.010
3. Kolodny A, Courtwright DT, Hwang CS, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction.Annu Rev Public Health . Mar 18 2015;36:559-74. doi:10.1146/annurev-publhealth-031914-122957
4. Vital signs: overdoses of prescription opioid pain relievers and other drugs among women–United States, 1999-2010. MMWR Morb Mortal Wkly Rep . Jul 5 2013;62(26):537-42.
5. Barry DT, Beitel M, Joshi D, Schottenfeld RS. Pain and substance-related pain-reduction behaviors among opioid dependent individuals seeking methadone maintenance treatment. Am J Addict . Mar-Apr 2009;18(2):117-21. doi:10.1080/10550490902772470
6. Mun CJ, Beitel M, Oberleitner L, et al. Pain catastrophizing and pain acceptance are associated with pain severity and interference among methadone-maintained patients. J Clin Psychol . Dec 2019;75(12):2233-2247. doi:10.1002/jclp.22842
7. Oliveira D, Fontenele R, Weleff J, Sofuoglu M, De Aquino JP. Developing non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence. International Review of Psychiatry . 2023:1-20. doi:10.1080/09540261.2023.2229430
8. Fuehrlein BS, Ross DA. Opioid Use Disorder: A Desperate Need for Novel Treatments. Biol Psychiatry . Apr 1 2017;81(7):e43-e45. doi:10.1016/j.biopsych.2017.01.014
9. De Aquino JP, Parida S, Avila-Quintero VJ, et al. Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies.Drug Alcohol Depend . Nov 1 2021;228:109097. doi:10.1016/j.drugalcdep.2021.109097
10. Nichols DE. Psychedelics. Pharmacol Rev . Apr 2016;68(2):264-355. doi:10.1124/pr.115.011478
11. Savage C, McCabe OL. Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study. Arch Gen Psychiatry . Jun 1973;28(6):808-14. doi:10.1001/archpsyc.1973.01750360040005
12. Ludwig AM, Levine J. A CONTROLLED COMPARISON OF FIVE BRIEF TREATMENT TECHNIQUES EMPLOYING LSD, HYPNOSIS, AND PSYCHOTHERAPY. Am J Psychother . Jul 1965;19:417-35. doi:10.1176/appi.psychotherapy.1965.19.3.417
13. Kast EC, Collins VJ. STUDY OF LYSERGIC ACID DIETHYLAMIDE AS AN ANALGESIC AGENT. Anesth Analg . May-Jun 1964;43:285-91.
14. Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry . Oct 1 2022;79(10):953-962. doi:10.1001/jamapsychiatry.2022.2096
15. Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. Am J Drug Alcohol Abuse . Jan 2017;43(1):55-60. doi:10.3109/00952990.2016.1170135
16. Mosca A, Chiappini S, Miuli A, et al. Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: a Systematic Review of the Current Literature. Curr Neuropharmacol . Oct 17 2022;doi:10.2174/1570159x21666221017085612
17. van der Meer PB, Fuentes JJ, Kaptein AA, et al. Therapeutic effect of psilocybin in addiction: A systematic review. Front Psychiatry . 2023;14:1134454. doi:10.3389/fpsyt.2023.1134454
18. Liester MB. A review of lysergic acid diethylamide (LSD) in the treatment of addictions: historical perspectives and future prospects.Curr Drug Abuse Rev . 2014;7(3):146-56. doi:10.2174/1874473708666150107120522
19. Bogenschutz MP, Johnson MW. Classic hallucinogens in the treatment of addictions. Prog Neuropsychopharmacol Biol Psychiatry . Jan 4 2016;64:250-8. doi:10.1016/j.pnpbp.2015.03.002
20. Rodrigues LS, Rossi GN, Rocha JM, et al. Effects of ayahuasca and its alkaloids on substance use disorders: an updated (2016-2020) systematic review of preclinical and human studies. Eur Arch Psychiatry Clin Neurosci . Jun 2022;272(4):541-556. doi:10.1007/s00406-021-01267-7
21. Kelmendi B, Kaye AP, Pittenger C, Kwan AC. Psychedelics. Curr Biol . Jan 24 2022;32(2):R63-r67. doi:10.1016/j.cub.2021.12.009
22. Nakagawasai O, Arai Y, Satoh SE, et al. Monoamine oxidase and head-twitch response in mice. Mechanisms of alpha-methylated substrate derivatives. Neurotoxicology . Jan 2004;25(1-2):223-32. doi:10.1016/s0161-813x(03)00101-3
23. Silva MT, Calil HM. Screening hallucinogenic drugs: systematic study of three behavioral tests. Psychopharmacologia . May 28 1975;42(2):163-71. doi:10.1007/bf00429548
24. Yamamoto T, Ueki S. The role of central serotonergic mechanisms on head-twitch and backward locomotion induced by hallucinogenic drugs.Pharmacol Biochem Behav . Jan 1981;14(1):89-95. doi:10.1016/0091-3057(81)90108-8
25. de Vos CMH, Mason NL, Kuypers KPC. Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. Front Psychiatry . 2021;12:724606. doi:10.3389/fpsyt.2021.724606
26. Price DD. Psychological and neural mechanisms of the affective dimension of pain. Science . Jun 9 2000;288(5472):1769-72. doi:10.1126/science.288.5472.1769
27. Bardin L. The complex role of serotonin and 5-HT receptors in chronic pain. Behav Pharmacol . Sep 2011;22(5-6):390-404. doi:10.1097/FBP.0b013e328349aae4
28. Bondy B, Spaeth M, Offenbaecher M, et al. The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis . Oct 1999;6(5):433-9. doi:10.1006/nbdi.1999.0262
29. Nicholl BI, Holliday KL, Macfarlane GJ, et al. Association of HTR2A polymorphisms with chronic widespread pain and the extent of musculoskeletal pain: results from two population-based cohorts.Arthritis Rheum . Mar 2011;63(3):810-8. doi:10.1002/art.30185
30. Talbot K, Madden VJ, Jones SL, Moseley GL. The sensory and affective components of pain: are they differentially modifiable dimensions or inseparable aspects of a unitary experience? A systematic review.Br J Anaesth . Aug 2019;123(2):e263-e272. doi:10.1016/j.bja.2019.03.033
31. Okamoto K, Imbe H, Morikawa Y, et al. 5-HT2A receptor subtype in the peripheral branch of sensory fibers is involved in the potentiation of inflammatory pain in rats. Pain . Sep 2002;99(1-2):133-43. doi:10.1016/s0304-3959(02)00070-2
32. Patel R, Dickenson AH. Modality selective roles of pro-nociceptive spinal 5-HT(2A) and 5-HT(3) receptors in normal and neuropathic states.Neuropharmacology . Dec 2018;143:29-37. doi:10.1016/j.neuropharm.2018.09.028
33. Liu QQ, Yao XX, Gao SH, et al. Role of 5-HT receptors in neuropathic pain: potential therapeutic implications. Pharmacol Res . Sep 2020;159:104949. doi:10.1016/j.phrs.2020.104949
34. López-Giménez JF, González-Maeso J. Hallucinogens and Serotonin 5-HT(2A) Receptor-Mediated Signaling Pathways. Curr Top Behav Neurosci . 2018;36:45-73. doi:10.1007/7854_2017_478
35. Haleem DJ. Serotonin-1A receptor dependent modulation of pain and reward for improving therapy of chronic pain. Pharmacol Res . Aug 2018;134:212-219. doi:10.1016/j.phrs.2018.06.030
36. Seifert O, Baerwald C. Interaction of pain and chronic inflammation.Z Rheumatol . Apr 2021;80(3):205-213. Wechselwirkungen von Schmerz und chronischer Entzündung. doi:10.1007/s00393-020-00951-8
37. Flanagan TW, Nichols CD. Psychedelics as anti-inflammatory agents.Int Rev Psychiatry . Aug 2018;30(4):363-375. doi:10.1080/09540261.2018.1481827
38. Abbott FV, Hong Y, Blier P. Activation of 5-HT2A receptors potentiates pain produced by inflammatory mediators.Neuropharmacology . Jan 1996;35(1):99-110. doi:10.1016/0028-3908(95)00136-0
39. Puderbaugh M, Emmady PD. Neuroplasticity. StatPearls . StatPearls Publishing
Copyright © 2023, StatPearls Publishing LLC.; 2023.
40. Shen W, Tu Y, Gollub RL, et al. Visual network alterations in brain functional connectivity in chronic low back pain: A resting state functional connectivity and machine learning study. Neuroimage Clin . 2019;22:101775. doi:10.1016/j.nicl.2019.101775
41. Baliki MN, Mansour AR, Baria AT, Apkarian AV. Functional reorganization of the default mode network across chronic pain conditions. PLoS One . 2014;9(9):e106133. doi:10.1371/journal.pone.0106133
42. Baliki MN, Geha PY, Apkarian AV, Chialvo DR. Beyond feeling: chronic pain hurts the brain, disrupting the default-mode network dynamics.J Neurosci . Feb 6 2008;28(6):1398-403. doi:10.1523/jneurosci.4123-07.2008
43. Baliki MN, Petre B, Torbey S, et al. Corticostriatal functional connectivity predicts transition to chronic back pain. Nat Neurosci . Jul 1 2012;15(8):1117-9. doi:10.1038/nn.3153
44. Ly C, Greb AC, Cameron LP, et al. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep . Jun 12 2018;23(11):3170-3182. doi:10.1016/j.celrep.2018.05.022
45. Hipólito I, Mago J, Rosas FE, Carhart-Harris R. Pattern breaking: a complex systems approach to psychedelic medicine. Neurosci Conscious . 2023;2023(1):niad017. doi:10.1093/nc/niad017
46. Carhart-Harris RL, Chandaria S, Erritzoe DE, et al. Canalization and plasticity in psychopathology. Neuropharmacology . Mar 15 2023;226:109398. doi:10.1016/j.neuropharm.2022.109398
47. Gracely RH, Harte SE. Emotional/Affective Aspects of Pain. In: Binder MD, Hirokawa N, Windhorst U, eds. Encyclopedia of Neuroscience . Springer Berlin Heidelberg; 2009:1092-1095.
48. Kasanetz F, Acuña MA, Nevian T. Chapter 18 - Anterior cingulate cortex, pain perception, and pathological neuronal plasticity during chronic pain. In: Rajendram R, Patel VB, Preedy VR, Martin CR, eds.The Neurobiology, Physiology, and Psychology of Pain . Academic Press; 2022:193-202.
49. Carhart-Harris RL, Erritzoe D, Williams T, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin.Proc Natl Acad Sci U S A . Feb 7 2012;109(6):2138-43. doi:10.1073/pnas.1119598109
50. Barba T, Buehler S, Kettner H, et al. Effects of psilocybin versus escitalopram on rumination and thought suppression in depression.BJPsych Open . Sep 6 2022;8(5):e163. doi:10.1192/bjo.2022.565
51. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med . Nov 10 2003;163(20):2433-45. doi:10.1001/archinte.163.20.2433
52. Dick BD, Rashiq S. Disruption of attention and working memory traces in individuals with chronic pain. Anesth Analg . May 2007;104(5):1223-9, tables of contents. doi:10.1213/01.ane.0000263280.49786.f5
53. Linton SJ, Shaw WS. Impact of psychological factors in the experience of pain. Phys Ther . May 2011;91(5):700-11. doi:10.2522/ptj.20100330
54. Meier ML, Stämpfli P, Vrana A, Humphreys BK, Seifritz E, Hotz-Boendermaker S. Neural Correlates of Fear of Movement in Patients with Chronic Low Back Pain vs. Pain-Free Individuals. Front Hum Neurosci . 2016;10:386. doi:10.3389/fnhum.2016.00386
55. Schütze R, Rees C, Smith A, Slater H, O’Sullivan P. Metacognition, perseverative thinking, and pain catastrophizing: A moderated-mediation analysis. Eur J Pain . Jan 2020;24(1):223-233. doi:10.1002/ejp.1479
56. Ziadni MS, Sturgeon JA, Darnall BD. The relationship between negative metacognitive thoughts, pain catastrophizing and adjustment to chronic pain. Eur J Pain . Apr 2018;22(4):756-762. doi:10.1002/ejp.1160
57. Sweat NW, Bates LW, Hendricks PS. The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving. J Psychoactive Drugs . Nov-Dec 2016;48(5):344-350. doi:10.1080/02791072.2016.1234090
58. Millière R, Carhart-Harris RL, Roseman L, Trautwein FM, Berkovich-Ohana A. Psychedelics, Meditation, and Self-Consciousness.Front Psychol . 2018;9:1475. doi:10.3389/fpsyg.2018.01475
59. MacLean RR, Sofuoglu M, Brede E, Robinson C, Waters AJ. Attentional bias in opioid users: A systematic review and meta-analysis. Drug Alcohol Depend . Oct 1 2018;191:270-278. doi:10.1016/j.drugalcdep.2018.07.012
60. Schoth DE, Nunes Vd Fau - Liossi C, Liossi C. Attentional bias towards pain-related information in chronic pain; a meta-analysis of visual-probe investigations. (1873-7811 (Electronic))
61. MacLean RR, Heapy AA, Waters AJ, et al. Integrating cognitive bias modification for pain and opioid cues into medication for opioid use disorder clinical care: Feasibility, acceptability, and preliminary results. (1879-0046 (Electronic))
62. Griffiths RR, Johnson MW, Richards WA, et al. Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors.J Psychopharmacol . Jan 2018;32(1):49-69. doi:10.1177/0269881117731279
63. Forstmann M, Yudkin DA, Prosser AMB, Heller SM, Crockett MJ. Transformative experience and social connectedness mediate the mood-enhancing effects of psychedelic use in naturalistic settings.Proc Natl Acad Sci U S A . Feb 4 2020;117(5):2338-2346. doi:10.1073/pnas.1918477117
64. Weiss B, Nygart V, Pommerencke LM, Carhart-Harris RL, Erritzoe D. Examining Psychedelic-Induced Changes in Social Functioning and Connectedness in a Naturalistic Online Sample Using the Five-Factor Model of Personality. Front Psychol . 2021;12:749788. doi:10.3389/fpsyg.2021.749788
65. Ong AD, Thoemmes F, Ratner K, Ghezzi-Kopel K, Reid MC. Positive affect and chronic pain: a preregistered systematic review and meta-analysis. (1872-6623 (Electronic))
66. Whelan A, Johnson MI. Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role?Pain Manag . May 2018;8(3):217-229. doi:10.2217/pmt-2017-0068
67. Ramaekers JG, Hutten N, Mason NL, et al. A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. J Psychopharmacol . Apr 2021;35(4):398-405. doi:10.1177/0269881120940937
68. Reiche S, Hermle L, Gutwinski S, Jungaberle H, Gasser P, Majić T. Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review.Prog Neuropsychopharmacol Biol Psychiatry . Feb 2 2018;81:1-10. doi:10.1016/j.pnpbp.2017.09.012
69. Kooijman NI, Willegers T, Reuser A, et al. Are psychedelics the answer to chronic pain: A review of current literature. Pain Pract . Apr 2023;23(4):447-458. doi:10.1111/papr.13203
70. Grof S, Goodman LE, Richards WA, Kurland AA. LSD-assisted psychotherapy in patients with terminal cancer. Int Pharmacopsychiatry . 1973;8(3):129-44. doi:10.1159/000467984
71. Kurland AA. LSD in the supportive care of the terminally ill cancer patient. J Psychoactive Drugs . Oct-Dec 1985;17(4):279-90. doi:10.1080/02791072.1985.10524332
72. Fuentes JJ, Fonseca F, Elices M, Farré M, Torrens M. Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials. Front Psychiatry . 2019;10:943. doi:10.3389/fpsyt.2019.00943
73. Karst M, Halpern JH, Bernateck M, Passie T. The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series. Cephalalgia . Sep 2010;30(9):1140-4. doi:10.1177/0333102410363490
74. Andersson M, Persson M, Kjellgren A. Psychoactive substances as a last resort-a qualitative study of self-treatment of migraine and cluster headaches. Harm Reduct J . Sep 5 2017;14(1):60. doi:10.1186/s12954-017-0186-6
75. Fadiman J, Korb S. Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration. J Psychoactive Drugs . Apr-Jun 2019;51(2):118-122. doi:10.1080/02791072.2019.1593561
76. Sewell RA, Halpern JH, Pope HG, Jr. Response of cluster headache to psilocybin and LSD. Neurology . Jun 27 2006;66(12):1920-2. doi:10.1212/01.wnl.0000219761.05466.43
77. Schindler EA, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell RA. Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey. J Psychoactive Drugs . Nov-Dec 2015;47(5):372-81. doi:10.1080/02791072.2015.1107664
78. Subedi B, Grossberg GT. Phantom limb pain: mechanisms and treatment approaches. Pain Res Treat . 2011;2011:864605. doi:10.1155/2011/864605
79. Fanciullacci M, Bene ED, Franchi G, Sicuteri F. Brief report: Phantom limp pain: sub-hallucinogenic treatment with lysergic acid diethylamide (LSD-25). Headache . Jul 1977;17(3):118-9. doi:10.1111/j.1526-4610.1977.hed1703118.x
80. Kuromaru S, Okada S, Hanada M, Kasahara Y, Sakamoto K. The effect of LSD on the phantom limb phenomenon. J Lancet . Jan 1967;87(1):22-7.
81. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.J Psychopharmacol . Dec 2016;30(12):1181-1197. doi:10.1177/0269881116675513
82. Schindler EAD, Sewell RA, Gottschalk CH, et al. Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin.Neurotherapeutics . Jan 2021;18(1):534-543. doi:10.1007/s13311-020-00962-y
83. Medicine USNLo. Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication. 2023.
84. McKenna DJ. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacol Ther . May 2004;102(2):111-29. doi:10.1016/j.pharmthera.2004.03.002
85. Bouso CSaJC. Ayahuasca: From the Amazon to the Global Villag. Transnational Institute; 2015.
86. Jiménez-Garrido DF, Gómez-Sousa M, Ona G, et al. Effects of ayahuasca on mental health and quality of life in naïve users: A longitudinal and cross-sectional study combination. Sci Rep . Mar 5 2020;10(1):4075. doi:10.1038/s41598-020-61169-x
87. Barbosa PC, Cazorla IM, Giglio JS, Strassman R. A six-month prospective evaluation of personality traits, psychiatric symptoms and quality of life in ayahuasca-naïve subjects. J Psychoactive Drugs . Sep 2009;41(3):205-12. doi:10.1080/02791072.2009.10400530
88. Goutarel RG, Otto; Sillans, Roger. Pharmacodynamics and Therapeutic Applications of Iboga and Ibogaine. Psychedelic Monographs and Essays 1993 6 71-1111996.
89. Bagal AA, Hough LB, Nalwalk JW, Glick SD. Modulation of morphine-induced antinociception by ibogaine and noribogaine.Brain Res . Nov 25 1996;741(1-2):258-62. doi:10.1016/s0006-8993(96)00938-9
90. Sunder Sharma S, Bhargava HN. Enhancement of morphine antinociception by ibogaine and noribogaine in morphine-tolerant mice.Pharmacology . Nov 1998;57(5):229-32. doi:10.1159/000028246
91. Weleff J, Akiki TJ, Barnett BS. Bibliometric Analysis of Academic Journal Articles Reporting Results of Psychedelic Clinical Studies.J Psychoactive Drugs . Sep-Oct 2023;55(4):434-444. doi:10.1080/02791072.2022.2133757
92. Pisano VD, Putnam NP, Kramer HM, Franciotti KJ, Halpern JH, Holden SC. The association of psychedelic use and opioid use disorders among illicit users in the United States. J Psychopharmacol . May 2017;31(5):606-613. doi:10.1177/0269881117691453
93. Argento E, Socias ME, Hayashi K, et al. Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting. Int J Drug Policy . Feb 2022;100:103518. doi:10.1016/j.drugpo.2021.103518
94. Jones G, Ricard JA, Lipson J, Nock MK. Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample. Sci Rep . Apr 7 2022;12(1):4099. doi:10.1038/s41598-022-08085-4
95. Medicine USNLo. Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder (BIPOD-In). ClinicalTrials.gov2023.
96. Sobell LC, Sobell MB. Timeline Follow-Back. In: Litten RZ, Allen JP, eds. Measuring Alcohol Consumption: Psychosocial and Biochemical Methods . Humana Press; 1992:41-72.
97. Medicine USNLo. Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine. 2021.
98. Medicine USNLo. Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use. 2023.
99. Thomas G, Lucas P, Capler NR, Tupper KW, Martin G. Ayahuasca-assisted therapy for addiction: results from a preliminary observational study in Canada. Curr Drug Abuse Rev . Mar 2013;6(1):30-42. doi:10.2174/15733998113099990003
100. Hamill J, Hallak J, Dursun SM, Baker G. Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness. Curr Neuropharmacol . 2019;17(2):108-128. doi:10.2174/1570159x16666180125095902
101. Fábregas JM, González D, Fondevila S, et al. Assessment of addiction severity among ritual users of ayahuasca. Drug Alcohol Depend . Oct 1 2010;111(3):257-61. doi:10.1016/j.drugalcdep.2010.03.024
102. Argento E, Capler R, Thomas G, Lucas P, Tupper KW. Exploring ayahuasca-assisted therapy for addiction: A qualitative analysis of preliminary findings among an Indigenous community in Canada. Drug Alcohol Rev . Nov 2019;38(7):781-789. doi:10.1111/dar.12985
103. Mosca A, Chiappini S, Miuli A, et al. Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review of the Current Literature. Curr Neuropharmacol . 2023;21(11):2178-2194. doi:10.2174/1570159x21666221017085612
104. Mash DC, Kovera CA, Pablo J, et al. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann N Y Acad Sci . Sep 2000;914:394-401. doi:10.1111/j.1749-6632.2000.tb05213.x
105. Knuijver T, Schellekens A, Belgers M, et al. Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study. Addiction . Jan 2022;117(1):118-128. doi:10.1111/add.15448
106. Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse . 2018;44(1):37-46. doi:10.1080/00952990.2017.1310218
107. Davis AK, Renn E, Windham-Herman AM, Polanco M, Barsuglia JP. A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification. J Psychoactive Drugs . Sep-Oct 2018;50(4):287-297. doi:10.1080/02791072.2018.1487607
108. Mash DC, Duque L, Page B, Allen-Ferdinand K. Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes.Front Pharmacol . 2018;9:529. doi:10.3389/fphar.2018.00529
109. Malcolm BJ, Polanco M, Barsuglia JP. Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine. J Psychoactive Drugs . Jul-Aug 2018;50(3):256-265. doi:10.1080/02791072.2018.1447175
110. Medicine USNLo. Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification. 2022.
111. Medicine USNLo. A Study of Oral Ibogaine in Opioid Withdrawal. 2022;
112. Glue P, Lockhart M, Lam F, Hung N, Hung CT, Friedhoff L. Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. J Clin Pharmacol . Feb 2015;55(2):189-94. doi:10.1002/jcph.404
113. Bornemann J, Close JB, Spriggs MJ, Carhart-Harris R, Roseman L. Self-Medication for Chronic Pain Using Classic Psychedelics: A Qualitative Investigation to Inform Future Research. Front Psychiatry . 2021;12:735427. doi:10.3389/fpsyt.2021.735427
114. Lipton RB, Buse DC, Friedman BW, et al. Characterizing opioid use in a US population with migraine: Results from the CaMEO study.Neurology . Aug 4 2020;95(5):e457-e468. doi:10.1212/wnl.0000000000009324
115. Paice JA, Bohlke K, Barton D, et al. Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline. J Clin Oncol . Feb 1 2023;41(4):914-930. doi:10.1200/jco.22.02198
116. Delorme J, Kerckhove N, Authier N, Pereira B, Bertin C, Chenaf C. Systematic Review and Meta-Analysis of the Prevalence of Chronic Pain Among Patients With Opioid Use Disorder and Receiving Opioid Substitution Therapy. J Pain . Feb 2023;24(2):192-203. doi:10.1016/j.jpain.2022.08.008
117. Administration USFaD. Psychedelic Drugs: Considerations for Clinical Investigations. 2023.
118. Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol . Aug 2008;22(6):603-20. doi:10.1177/0269881108093587
119. Kiluk BD, Kleykamp BA, Comer SD, et al. Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A Review. JAMA Psychiatry . Jan 1 2023;80(1):84-92. doi:10.1001/jamapsychiatry.2022.4020
120. Mücke M, Cuhls H, Radbruch L, et al. Quantitative sensory testing (QST). English version. Schmerz . Nov 2021;35(Suppl 3):153-160. Quantitative sensorische Testung (QST). doi:10.1007/s00482-015-0093-2
121. Georgopoulos V, Akin-Akinyosoye K, Zhang W, McWilliams DF, Hendrick P, Walsh DA. Quantitative sensory testing and predicting outcomes for musculoskeletal pain, disability, and negative affect: a systematic review and meta-analysis. Pain . Sep 2019;160(9):1920-1932. doi:10.1097/j.pain.0000000000001590
122. Crombez G, Van Ryckeghem DML, Eccleston C, Van Damme S. Attentional bias to pain-related information: a meta-analysis. Pain . Apr 2013;154(4):497-510. doi:10.1016/j.pain.2012.11.013
123. Kiluk BD, Yip SW, DeVito EE, Carroll KM, Sofuoglu M. Anhedonia as a key clinical feature in the maintenance and treatment of opioid use disorder. Clin Psychol Sci . Nov 2019;7(6):1190-1206. doi:10.1177/2167702619855659
124. Saraiya TC, Jarnecke AM, Jones J, Brown DG, Brady KT, Back SE. Laboratory-induced stress and craving predict opioid use during follow-up among individuals with prescription opioid use disorder.Drug Alcohol Depend . Aug 1 2021;225:108755. doi:10.1016/j.drugalcdep.2021.108755
125. Glue P, Cape G, Tunnicliff D, et al. Ascending Single-Dose, Double-Blind, Placebo-Controlled Safety Study of Noribogaine in Opioid-Dependent Patients. Clin Pharmacol Drug Dev . Nov 2016;5(6):460-468. doi:10.1002/cpdd.254
126. Olson DE. The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects. ACS Pharmacol Transl Sci . Apr 9 2021;4(2):563-567. doi:10.1021/acsptsci.0c00192
127. Yaden DB, Griffiths RR. The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects. ACS Pharmacol Transl Sci . Apr 9 2021;4(2):568-572. doi:10.1021/acsptsci.0c00194
128. Roseman L, Nutt DJ, Carhart-Harris RL. Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. Front Pharmacol . 2017;8:974. doi:10.3389/fphar.2017.00974
129. Schindler EAD. Psychedelics in the Treatment of Headache and Chronic Pain Disorders. Curr Top Behav Neurosci . 2022;56:261-285. doi:10.1007/7854_2022_365
130. Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.J Psychopharmacol . Nov 2014;28(11):983-92. doi:10.1177/0269881114548296
131. Hoffman BM, Papas RK, Chatkoff DK, Kerns RD. Meta-analysis of psychological interventions for chronic low back pain. Health Psychol . Jan 2007;26(1):1-9. doi:10.1037/0278-6133.26.1.1
132. Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry . Feb 2008;165(2):179-87. doi:10.1176/appi.ajp.2007.06111851
133. Brennan W, Belser AB. Models of Psychedelic-Assisted Psychotherapy: A Contemporary Assessment and an Introduction to EMBARK, a Transdiagnostic, Trans-Drug Model. Front Psychol . 2022;13:866018. doi:10.3389/fpsyg.2022.866018
134. Cavarra M, Falzone A, Ramaekers JG, Kuypers KPC, Mento C. Psychedelic-Assisted Psychotherapy-A Systematic Review of Associated Psychological Interventions. Front Psychol . 2022;13:887255. doi:10.3389/fpsyg.2022.887255
135. Yaden DB, Berghella AP, Regier PS, Garcia-Romeu A, Johnson MW, Hendricks PS. Classic psychedelics in the treatment of substance use disorder: Potential synergies with twelve-step programs. Int J Drug Policy . Dec 2021;98:103380. doi:10.1016/j.drugpo.2021.103380
136. Pronovost-Morgan C, Hartogsohn I, Ramaekers JG. Harnessing placebo: Lessons from psychedelic science. J Psychopharmacol . Sep 2023;37(9):866-875. doi:10.1177/02698811231182602
137. Henderson LA, Di Pietro F, Youssef AM, et al. Effect of Expectation on Pain Processing: A Psychophysics and Functional MRI Analysis.Front Neurosci . 2020;14:6. doi:10.3389/fnins.2020.00006
138. Hovmand OR, Poulsen ED, Arnfred S, Storebø OJ. Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review.J Psychopharmacol . Jul 2023;37(7):649-659. doi:10.1177/02698811231180276
139. Szigeti B, Nutt D, Carhart-Harris R, Erritzoe D. The difference between ’placebo group’ and ’placebo control’: a case study in psychedelic microdosing. Sci Rep . Jul 26 2023;13(1):12107. doi:10.1038/s41598-023-34938-7
140. Gukasyan N, Nayak SM. Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy.Transcult Psychiatry . Oct 2022;59(5):652-664. doi:10.1177/1363461520983684
141. Gukasyan N, Davis AK, Barrett FS, et al. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol . Feb 2022;36(2):151-158. doi:10.1177/02698811211073759
142. Henningfield JE, Ashworth J, Heal DJ, Smith SL. Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective. J Psychopharmacol . Jan 2023;37(1):33-44. doi:10.1177/02698811221140004
143. Breeksema JJ, Kuin BW, Kamphuis J, van den Brink W, Vermetten E, Schoevers RA. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review. J Psychopharmacol . Oct 2022;36(10):1100-1117. doi:10.1177/02698811221116926
144. Johnston CB, Mangini M, Grob C, Anderson B. The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns.Am J Geriatr Psychiatry . Jan 2023;31(1):44-53. doi:10.1016/j.jagp.2022.08.007
145. Goodwin GM, Aaronson ST, Alvarez O, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med . Nov 3 2022;387(18):1637-1648. doi:10.1056/NEJMoa2206443
146. Halpern JH, Pope HG, Jr. Hallucinogen persisting perception disorder: what do we know after 50 years? Drug Alcohol Depend . Mar 1 2003;69(2):109-19. doi:10.1016/s0376-8716(02)00306-x
147. Rocha JM, Reis JAS, Bouso JC, Hallak JEC, Dos Santos RG. Identifying setting factors associated with improved ibogaine safety: a systematic review of clinical studies. Eur Arch Psychiatry Clin Neurosci . Oct 2023;273(7):1527-1542. doi:10.1007/s00406-023-01590-1
148. McIntyre RS. Serotonin 5-HT(2B) receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents. Expert Opin Drug Saf . Jul-Dec 2023;22(10):881-883. doi:10.1080/14740338.2023.2248883